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Abstract
Aims/hypothesis Metabolic dysregulation may precede the onset of type 1 diabetes. However, these metabolic disturbances and
their specific role in disease initiation remain poorly understood. In this study, we examined whether children who progress to
type 1 diabetes have a circulatory polar metabolite profile distinct from that of children who later progress to islet autoimmunity
but not type 1 diabetes and a matched control group.
Methods We analysed polar metabolites from 415 longitudinal plasma samples in a prospective cohort of children in three study
groups: those who progressed to type 1 diabetes; those who seroconverted to one islet autoantibody but not to type 1 diabetes; and
an antibody-negative control group. Metabolites were measured using two-dimensional GC high-speed time of flight MS.
Results In early infancy, progression to type 1 diabetes was associated with downregulated amino acids, sugar derivatives and
fatty acids, including catabolites of microbial origin, compared with the control group. Methionine remained persistently upreg-
ulated in those progressing to type 1 diabetes compared with the control group and those who seroconverted to one islet
autoantibody. The appearance of islet autoantibodies was associated with decreased glutamic and aspartic acids.
Conclusions/interpretation Our findings suggest that children who progress to type 1 diabetes have a unique metabolic profile,
which is, however, altered with the appearance of islet autoantibodies. Our findings may assist with early prediction of the disease.
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FDR False discovery rate
GADA GAD autoantibodies
IAA Insulin autoantibodies
ICA Islet cell antibodies
MetPA Metabolic pathway analysis
P1Ab Individuals who tested positive for at least
one antibody in a minimum of two
consecutive samples but did not progress
to clinical type 1 diabetes during the
follow-up
PCA Principal component analysis
PT1D Progressors to type 1 diabetes
RU Relative units
Introduction
Type 1 diabetes is an autoimmune disease that arises as a
consequence of the destruction of insulin-producing pancreat-
ic beta cells by the immune system [1]. The incidence of type
1 diabetes is highest in children and adolescents in the devel-
oped countries [2] and an increase in disease rate is expected
in young children aged under 5 years [3]. To reverse the in-
creasing rate, early prediction and prevention of type 1 diabe-
tes is essential. However, the aetiology of type 1 diabetes is
complex and multifactorial, and the primary cause for initia-
tion and disease progression is poorly understood [1].
Therefore, predictive and preventive measures for type 1 dia-
betes remain unmet medical needs.
HLA complex alleles constitute the most relevant and the
strongest genetic risk factor for type 1 diabetes susceptibility
[4]. However, only 3–10% of the individuals with risk HLA
loci develop type 1 diabetes [5], indicating that exogenous
factors such as environmental exposure, diet and gut microbi-
ota likely play a vital role in disease progression [6]. Initiation
of beta cell autoimmunity is the first detectable sign of pro-
gression towards type 1 diabetes. However, seroconversion to
islet autoantibody positivity may not lead to overt diabetes [7]
and the period between seroconversion and the appearance of
clinical symptoms of type 1 diabetes may vary between indi-
viduals from a few months to many years [8, 9].
Previous studies suggest that children who progress to type
1 diabetes have dysregulated metabolic profiles in infancy
[10–13], prior to the seroconversion for islet autoantibodies.
However, studies in humans have so far mainly focused on
lipids, and there is relatively little information on polar metab-
olites, such as those involved in central metabolic pathways,
in relation to type 1 diabetes pathogenesis. Here, we study
circulating polar metabolite profiles in progression to type 1
diabetes in a longitudinal study setting.
Methods
These methods are expanded versions of descriptions in our
related work [10].
Study settingThe plasma samples were from the Finnish Type
1 Diabetes Prediction and Prevention (DIPP) study [14]. The
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participants in the current study were from the Tampere cohort
[15]. The ethics and research committee of the participating
university hospital approved the study protocol and the study
followed the guidelines of the Declaration of Helsinki. Parents
of all participants gave written informed consent at the begin-
ning of the study. The samples were collected at up to six
different time points, corresponding to the ages of 3, 6, 12,
18, 24 and 36 months (or above). This longitudinal cohort
comprises samples from 120 children: 40 progressors to type
1 diabetes (PT1D); 40 who tested positive for at least one
antibody in a minimum of two consecutive samples but did
not progress to clinical type 1 diabetes during the follow-up
(P1Ab); and 40 control (CTRL) children who remained islet
autoantibody-negative during the follow-up until the age of
15 years. We matched the participants in the three study
groups for HLA-associated diabetes risk, sex and period of
birth (electronic supplementary material [ESM] Table 1). In
total, we collected 415 non-fasting blood samples.
We separated plasma within 30 min of blood collection by
centrifugation at 1600 g for 20 min at room temperature. The
plasma samples were stored at −80°C until analysed.
HLA genotyping HLA-conferred susceptibility to type 1 dia-
betes was analysed using cord blood samples as described by
Nejentsev et al [16]. Briefly, the HLA genotyping was per-
formed with a time-resolved fluorometry-based assay for four
alleles using lanthanide-chelate-labelled sequence-specific ol-
igonucleotide probes detecting DQB1*02, DQB1*03:01,
DQB1*03:02 and DQB1*06:02/3 alleles [17]. Carriers of
DQB1*02/DQB1*03:02 or DQB1*03:02/x genotypes (here
x ≠DQB1*02, DQB1*03:01, DQB1*06:02, or DQB1*06:03
alleles) were categorised into the type 1 diabetes risk group
and recruited for the follow-up programme.
Detection of islet autoantibodies The participants were pro-
spectively observed for the appearance of islet cell antibodies
(ICA), insulin autoantibodies (IAA), islet antigen 2 autoanti-
bodies (IA-2A), and GAD autoantibodies (GADA), as de-
scribed previously [18]. ICA were detected with the use of
indirect immunofluorescence, whereas the other three autoan-
tibodies were quantified with the use of specific radiobinding
assays [19]. We used cut-off limits for positivity of 2.5 JDRF
units for ICA, 3.48 relative units (RU) for IAA, 5.36 RU for
GADA and 0.43 RU for IA-2A.
Analysis of polar metabolites After randomisation and
blinding, 415 plasma (30 μl aliquot) samples were used for
extraction. Polar metabolites were extracted in methanol
(400 μl), as previously described [20]. For quality control
and normalisation, a group-specific internal standard mix of
heptadecanoic acid-d33 (175.36 mg/l), valine-d8 (35.72 mg/
l), succinic acid-d4 (58.54 mg/l) and glutamic acid-d5
(110.43 mg/l) (Sigma-Aldrich, Steinheim, Germany) was
added to the extraction solvent. Samples were vortexed and
left to precipitate for 30 min on ice. After precipitation, ex-
tracts were centrifuged (centrifuge 5427 R; Eppendorf,
Hamburg, Germany) for 3 min on 12,520 g. A 180 μl sample
of supernatant fraction was transferred into GC vials and
stored for further use. The same procedure was applied for
clinic-pooled plasma, which was used for quality control and
batch correction. The quantification was performed using cal-
ibration curves prepared using the following standards
(Sigma-Aldrich): fumaric acid, aspartic acid, succinic acid,
malic acid, methionine, tyrosine, glutamic acid, phenylala-
nine, arachidonic acid, isoleucine, 3-hydroxybutyric acid, gly-
cine, threonine, leucine, proline, serine, valine, alanine, stearic
acid, linoleic acid, palmitic acid and oleic acid. Standards were
dissolved in methanol. The calibration curves included at least
six concentration points that ranged from 1 ng/sample to
3000 ng/sample, depending on the abundance in plasma. R2
was from 97.1% up to 99.9%.
Derivatisation was performed instrumentally using an
MPS2 (Gerstel, Mülheim an der Ruhr, Germany). Samples
were evaporated to dryness and derivatisation was performed
in two steps (details are in the ESM Methods). Derivatised
compounds were analysed using a Pegasus 4D system
(LECO, St Joseph, MI, USA). The method used is based on
two-dimensional GC followed by high-speed time of flight
acquisition of electron-ionisation-fragmented mass spectra.
The primary column had internal dimensions 10 m ×
0.18 mm (Rxi-5 ms, Restek Bellefonte, PA, USA) and the
secondary column was 1.5 m × 0.1 mm (BPX-50, SGE
Analytical Science, Austin, TX, USA). The system was
guarded by a retention gap column of deactivated silica (inter-
nal dimensions 1.7 m, 0.53 mm, fused silica deactivated;
Agilent Technologies, CA, USA). The modulator used nitro-
gen gas, which was cryogenically cooled. The second dimen-
sion cycle was 4 s. The temperature programme started at
50°C (2 min), then a gradient of 7°C up to 240°C was applied
and then finally a gradient of 25°/min to 300°C, where it was
held stable for 3 min. The temperature programme of the
secondary column was maintained at 20°C higher than the
primary column. The acquisition rate was kept at 100 Hz.
The instrument was guided by ChromaTOF software (version
4.32, LECO), which was also used for calculating the area
under the peaks with SN>100 and the identification of poten-
tial peaks using National Institute of Standards and
Technology 14 mass spectral library and in-house library.
The processing method included calculation of retention indi-
ces. Selected compounds were quantified against external cal-
ibration curves, after normalisation with internal standards,
and the rest of the metabolites were normalised against inter-
nal standards, as described by Hartonen et al [20].
Results were exported as text files for further processing
with Guineu [21] software; we used a 70 cut-off for peak
detection and the missing values were imputed using the
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nearest-neighbour method in MATLAB 2017b (Mathworks,
Natick, MA, USA), using default variable in the statistical
toolbox. A total of 75 pooled human plasma samples were
analysed for quality control purposes after every tenth sample.
In addition, blank samples were analysed after every sixth
sample and standard samples were analysed in each batch.
The relative SD (RSD) of the concentrations was <30% for
all quantified metabolites in the quality control samples, and
the raw variation of the internal standards in all of the samples
was also <30%. The overall %CVs across the analysis (all 415
samples) are shown in ESM Table 2.
Data analysis All statistical analyses were performed on log-
transformed data. The transformed data were mean centred
and auto scaled prior to multivariate analysis. Themultivariate
analysis was done using the PLS Toolbox 8.2.1 (Eigenvector
Research, Manson,WA, USA) inMATLAB 2017b. ANOVA-
simultaneous component analysis (ASCA) was performed to
induce different factors such age, sex, case and their interac-
tion [22]. ASCA is a multivariate extension of ANOVA used
for univariate data analysis. The ASCA method exploits dif-
ferent factors in the experimental design, for example, sex and
age, to allow easy interpretation of the variation induced by
these factors and their interactions in multivariate datasets
[22].
A Wilcoxon rank-sum test was performed for comparing
the two study groups of samples (e.g. PT1D vs P1Ab) in a
specific age cohort. For comparison, one sample per partici-
pant, closest to the age within the time window, has been used
in each test. Paired Student’s t test was performed for the
matched groups of samples (e.g. before vs after seroconver-
sion). The resulting nominal p values were corrected for mul-
tiple comparisons using the Benjamin and Hochberg approach
[23]. Adjusted p values <0.1 (q values) were considered sig-
nificantly different among the group of hypotheses tested in a
specific age cohort. All of the univariate statistical analyses
were computed in MATLAB 2017b using the statistical tool-
box. The fold difference was calculated by dividing the mean
concentration of a metabolite species in one group by another:
for instance, mean concentration in the PT1D group by the
mean concentration in the P1Ab group, and then illustrated by
heat maps. The locally weighted regression plot was made
using smoothing interpolation function loess (with span = 1)
available from the ggplot2 [24] package in R [25]. The indi-
vidual metabolite levels were visualised as a box plot using
GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA).
Pathway analysis of the significant metabolites (nominal
p values <0.05) was performed in MetaboAnalyst 4.0 [26].
The compounds unmatched during compound namematching
were excluded from the subsequent pathway analysis. We
implemented globaltest hypergeometric testing for the func-
tional enrichment analysis. The pathway topological analysis
was based on the relative betweenness measures of a
metabolite in a given metabolic network and for calculating
the pathway impact score. Based on the impact values from
the pathway topology analysis, the impact value threshold was
set to >0.10.
Results
Impact of age on circulating metabolome We performed a
metabolomics analysis of polar metabolites in plasma from
120 children, divided into three study groups: those who
progressed to type 1 diabetes (n = 40); those who
seroconverted to at least one autoantibody positivity but with-
out clinical symptoms of type 1 diabetes (n = 40); and a
matched antibody-negative control group (n = 40). For each
participant, plasma samples were collected corresponding to
the ages of 3, 6, 12, 18, 24 and 36 months (Fig. 1). We detect-
ed metabolites (n = 94) from across a wide range of chemical
classes, including amino acids, carboxylic acids (mainly
NEFA and other organic acids), hydroxyacids, phenolic com-
pounds, alcohols and sugar derivatives.
Principal component analysis (PCA) [27] of the complete
dataset including identified metabolites displayed an age-
dependent pattern (ESM Fig. 1). To resolve the impact of
age on the plasma metabolome, we performed ASCA by in-
corporating three factors—age, sex and study group (CTRL,
P1Ab, PT1D)—and their interactions. As expected, age-
related variation displayed the maximum effect (4.2%, nomi-
nal p = 0.001) in the circulating metabolome compared with
the impact of the other two factors, study group (1.2%, nom-
inal p = 0.001) and sex (0.5%, nominal p = 0.002). Notably,
the interaction factor ‘age and group’ also showed a signifi-
cant effect (2.9%, nominal p = 0.033), while interactions be-
tween other factors (age/sex and group/sex) remained insig-
nificant (nominal p values: p = 0.508 and p = 0.221,
respectively).
The scores from the first principal component (PC1) of the
factor ‘age’ clearly showed an age-related trajectory in the
circulatory metabolites (Fig. 2). The loading revealed high
levels of branched-chain amino acids (BCAA) in the 18, 24
and 36month age cohorts, whereas tryptophan, 3-indoleacetic
acid (tryptophan derivative) and carboxylic acids (mainly
NEFA)were elevated during early infancy (at 3 and 6months).
However, we did not detect any age-dependent patterns in
phenolic compounds, alcohols, hydroxyacids or sugar deriva-
tives (ESM Fig. 2).
Metabolite profiles during progression to islet autoimmunity
and type 1 diabetesConsidering age as a major confounder in
the plasma metabolome, we performed age-matched compar-
isons between the three study groups (CTRL, P1Ab and
PT1D). Univariate analysis revealed that all major metabolite
classes, including amino acids, NEFA and sugar derivatives,
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were altered in children who later progressed to type 1 diabe-
tes, with these changes evident in infancy (Fig. 3). Altogether,
15 metabolites were different between PT1D and CTRL
groups at 3 months of age (nominal p value <0.05). Nine out
of 15 metabolites were significantly lower at 3 months in the
PT1D compared with the CTRL group (adjusted p < 0.1; false
discovery rate [FDR] threshold of 0.1) (Fig. 3, ESM Table 3).
In order to assess if sex had an impact on plasma metabolite
levels in children at 3 months of age, we carried out an ASCA
with, as factors, study group and sex, and their interaction.
When evaluating the statistics from these factors, we found
only study group had a significant effect (nominal p = 0.012),
while sex and its interaction remained insignificant (nominal
p values: p = 0.081 and p = 0.73, respectively). The score of
the factor ‘study group’ showed distinct metabolic clusters
between PT1D, P1Ab and CTRL, suggesting that specific
metabolic changes precede islet autoimmunity and type 1 di-
abetes. The loadings disclosed that methionine, 2-
ketoisocaproic acid, bisphenol A (BPA), pyruvic acid,
glycerol-2-phosphate and levoglucosan were higher in the
PT1D group compared with the P1Ab and CTRL groups
(ESM Fig. 3).
Fig. 2 PCA score plots of the factor age, based on ASCA. These scores
represent the metabolomics dataset arranged according to age in the PCA
score plot. Each sample is represented by a point and coloured according
to the age. The x-axis shows the samples arranged by factor age while the
y-axis represents the sample score. Samples with similar scores cluster
together
Fig. 1 An overview of the study
design. The study cohort
comprised children who
progressed to type 1 diabetes,
children who seroconverted to
one islet autoantibody but did not
progress to type 1 diabetes during
the follow-up, and a group who
remained islet-autoantibody-
negative during the follow-up
until the age of 15 years. For each
child, longitudinal plasma
samples were drawn,
corresponding to the ages of 3, 6,
12, 18, 24 and 36 months. In each
age cohort and study group, the
number of autoantibody-positive
children is marked and
represented with a Y (antibody)
shape. TOF, time of flight
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At 6 months of age, altogether 20 metabolites differed be-
tween PT1D and CTRL (nominal p value <0.05). Fifteen of
these circulating metabolites passed the FDR threshold of 0.1
(Fig. 3a–d, ESM Table 4), including several amino acids,
sugar derivatives, NEFA and various other organic acids.
The levels of most of these metabolites decreased in type 1
diabetes progressors during the same period compared with
CTRL. Only methionine was found to be increased in PT1D
Fig. 3 Comparison of metabolomes in three study groups in different age
cohorts. (a) Heat map showing 43 metabolites representative of different
metabolic classes that change between PT1D, P1Ab and CTRL.
Differences in metabolite concentrations were calculated by dividing
the mean concentration of a metabolite species in one group by another
(PT1D/CTRL, PT1D/P1Ab or P1Ab/CTRL). The n values on the top row
represent the numerators and n values on the bottom row are the denom-
inators for each calculation. Crosses indicate adjusted p < 0.1. (b) Local
polynomial regression fitting (LOESS) curve plot of methionine concen-
tration over time for the three study groups. Blue, CTRL; green, P1Ab;
red, PT1D. Solid line, mean value; grey shaded area, 95% CI. (c)
Concentration of 4-hydroxyphenyllactic acid at 6 months of age. (d)
Concentration of glutamic acid at 6 months of age. In (c) and (d), the line
within each box represents the median, and the top and bottom of the box
represent the 75th and 25th percentiles, respectively. The whiskers indi-
cate the maximum and minimum values. †Adjusted p < 0.1
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compared with CTRL at the age of 6 months (Fig. 3b). In
addition, multivariate ASCA revealed that only study group
(CTRL, P1Ab and PT1D) had a significant effect (nominal
p = 0.004) on the plasma metabolites of children aged
6 months, whereas the impact of sex (nominal p = 0.180)
and its interaction with study group (nominal p = 0.269)
remained insignificant.
Next, we sought to examine whether children across the
three study groups had altered plasma metabolite levels in the
age cohorts of 12, 18, 24 and 36 months. With the exceptions
of 1-dodecanol and glycolic acid, no other statistically signif-
icant differences between the study groups were observed
(adjusted p < 0.1; FDR threshold of 0.1). At 36 months of
age, the dodecanol level was higher in the PT1D compared
with the CTRL group. Meanwhile, glycolic acid was lower in
the PT1D compared with the P1Ab group at 18months of age.
However, these metabolites showed inconsistent trends in the
longitudinal series (Fig. 3).
We also studied whether the pattern of a group of metabo-
lites seen at an early age was associated with a specific meta-
bolic pathway. The altered metabolites (nominal p < 0.05) be-
tween CTRL and PT1D at 3 and 6 months of age were sub-
jected to metabolic pathway analysis (MetPA) in
MetaboAnalyst [26]. In line with findings at the individual
metabolite level, we found that four metabolic pathways
remained altered between PT1D and CTRL groups at the
age of 3 months (Fig. 4a, ESM Table 5): linoleic acid metab-
olism; arachidonic acid metabolism; alanine, aspartate and
glutamate metabolism; and D-glutamine and D-glutamate
metabolism Similarly, at 6 months of age, MetPA revealed
that alanine, aspartate and glutamate metabolism, D-glutamine
and D-glutamate metabolism, tryptophan metabolism, argi-
nine and proline metabolism, as well as aminoacyl-tRNA bio-
synthesis remained dysregulated between the CTRL and
PT1D groups (Fig. 4b, ESM Table 6).
Metabolome before and after the first appearance of islet
autoantibodies In order to study the effect of islet seroconver-
sion on the metabolome, we compared metabolite levels be-
fore and after the appearance of first islet autoantibody in
P1Ab and PT1D groups. Pairwise comparison revealed that
11 metabolites were altered by seroconversion in the P1Ab
group (nominal p value <0.05, ESM Table 7), with four pass-
ing the FDR threshold of 0.1 (glutamic, aspartic, malic and
3,4-dihydroxybutanoic acids) (Fig. 5a–c). We detected seven
metabolites altered before and after islet autoantibody appear-
ance in the PT1D group (nominal p value <0.05), but none of
these passed the FDR threshold of 0.1 (ESM Table 8).
Metabolic pathway analysis corroborated these findings and
revealed that alanine, aspartate and glutamate metabolism
were altered when comparing the pathways before and after
seroconversion within P1Ab and PT1D groups (Fig. 5d, e).
However, the level of impact for these pathways varied be-
tween the P1Ab and PT1D groups, with impact values 0.441
and 0.176, respectively. Other relevant pathways and their
impact are summarised in ESM Tables 9 and 10. When exam-
ining metabolite level changes in relation to the appearance of
specific islet autoantibodies (ICA, IAA, islet antigen 2
Fig. 4 Pathway analysis of metabolites for which there were significant
differences in levels between the CTRL and PT1D groups at (a) 3 and (b)
6 months of age (nominal p < 0.05). The pathways are shown according
to the p values from the pathway enrichment analysis and pathway impact
values from the pathway topology analysis. The metabolic pathways with
impact value >0.1 were considered the most relevant pathways involved.
Pathway impact values were calculated from pathway topology analysis
using MetaboAnalyst. Circle size represents the pathway impact (the
larger the circle, the higher the impact) and the colour gradient, from
red to yellow, indicates the –log10(p value), with deep red indicating the
highest –log10(p value) and pale yellow indicating the lowest. tRNA,
transfer RNA
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autoantibodies [IA-2A] and GADA), no specific associations
were identified, which may be a consequence of the small
number of cases per individual autoantibody.
Discussion
Our study identified specific metabolic disturbances in chil-
dren who progressed to type 1 diabetes compared with an age-
matched control group and children who developed a single
islet autoantibody but did not progress to type 1 diabetes dur-
ing follow-up. We found that such metabolic dysregulation
exists before the first signs of islet autoimmunity. In agree-
ment with earlier studies [10, 28, 29], a strong association was
observed between the metabolome and age. We identified a
distinct plasma amino acid profile in PT1D children,
particularly at the ages of 3 and 6 months. Glutamic and
aspartic acids as well as tryptophan remained downregulated
during early infancy in the PT1D group compared with the
CTRL group, but not the P1Ab group. In our previous study
of polar metabolites in type 1 diabetes progression, we found
no significant difference in different age cohorts when com-
paring PT1D and CTRL groups [13]; this may, however, be
attributable to the small number of individuals in the metabo-
lomics part of that study. Notably, and in agreement with the
previous study, we also observed that the appearance of islet
cell autoantibodies was associated with the downregulation of
aspartic and glutamic acids [13], also corroborated by ob-
served change in alanine, aspartate and glutamate metabolism
in the MetPA.
Our findings are consistent with a previous study suggest-
ing that amino acid dysregulation precedes the appearance of
Fig. 5 The effect of islet autoantibody positivity on metabolite profiles.
(a) The most discriminating metabolites between the last available sam-
ples obtained before the first islet autoantibody appeared and the first
available samples after the emergence of the first islet autoantibody in
the P1Ab and PT1D groups. Crosses indicate adjusted p < 0.1. The
pairwise scatter plot of (b) aspartic and (c) glutamic acid before and after
the first appearance of islet autoantibodies. Pathway enrichment analysis
of differentially expressed metabolites before and after seroconversion in
(d) P1Ab and (e) PT1D. The pathways showing the largest difference
include alanine, aspartate and glutamate metabolism. Circle size repre-
sents the pathway impact (the larger the circle, the higher the impact) and
the colour gradient, from red to yellow, indicates the –log10(p value), with
deep red indicating the highest –log10(p value) and pale yellow indicating
the lowest. †Adjusted p < 0.1-A, after seroconversion; B, before serocon-
version, tRNA, transfer RNA
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islet autoantibodies and progression to type 1 diabetes [12].
Several NEFA were also downregulated at 3 months of age.
During basal metabolic processes, triacylglycerols are broken
down to fatty acids and glycerol [30]. Fatty acids act as an
important fuel source for cells, which is required to maintain
systematic energy homeostasis [31]. Usually, under conditions
when carbohydrate availability is limited, the fatty acids are an
alternative substrate for energy production [32]. Here, the de-
crease in fatty acids may be an indication of increased energy
demand in individuals in the PT1D group, further substantiat-
ed by the diminishment of circulating sugar derivatives as well
as altered linoleic acid metabolism and arachidonic acid me-
tabolism. This is also in line with our previous report [10]
associating downregulated triacylglycerols and phospholipids
in the PT1D group, supporting the view that altered energy
metabolism is involved in the initiation of the autoimmune
process and type 1 diabetes.
Accumulating evidence suggests that perturbations in the
gut microbial structure are associated with, and contribute to,
the pathogenesis of beta cell autoimmunity and overt type 1
diabetes [33–35]. Here, we found that 4-hydroxyphenyllactic
acid [36, 37], 11-eicosenoic acid [38] and succinic acid [39],
metabolites of potential microbial origin (catabolites), were
significantly downregulated at an early age (3 and 6 months)
in the PT1D group (nominal p < 0.05). The tryptophan-
derived microbial catabolite 3-indoleacetic also appeared to
be downregulated in PT1D (nominal p value <0.05, ESM
Fig. 4). As catabolites generated by the gut microbes are vital
to the intestinal homeostasis [37, 40], dysregulated microbial
catabolism may contribute to the dysbiosis associated with
progression to type 1 diabetes.
While most of the amino acids were downregulated in the
PT1D group compared with the CTRL and P1Ab groups,
methionine remained persistently upregulated in type 1 diabe-
tes progressors. This appears to be in disagreement with pre-
vious studies in BABYDIAB and Environmental Triggers for
Type 1 Diabetes (MIDIA) cohorts, which showed a decreased
level of methionine in autoantibody-positive individuals and
type 1 diabetes progressors, respectively [29, 41]. This dis-
crepancy may, however, be explained: [1] the BABYDIAB
study compared children seroconverting early in life (≤2 years)
with those who developed autoantibodies at an older age;
while [2] the MIDIA study highlighted differences that were
mainly linked to the age of the children and the duration of
breastfeeding [41]. We performed a similar comparison to that
of BABYDIAB in the current study setting but found no sig-
nificant differences between the groups (nominal p > 0.05).
The observed differences suggest disrupted methionine
metabolism in the PT1D group. Methionine can be salvaged
endogenously by protein/homocysteine degradation, poly-
amine synthesis or by the transsulfuration pathway [42], and
the disturbances in these pathways could modulate neonatal
epigenetic processes, including the DNA methylation and
chromatin remodelling and consequently influence various
immunological responses [43].
Multivariate ASCA revealed that plasma BPA was upreg-
ulated in the PT1D group, though univariate analysis across
different age cohorts did not reveal significant changes (nom-
inal p > 0.05) between the groups. Studies in an experimental
model of autoimmune diabetes suggest that increased BPA
exposure is associated with accelerated development of auto-
immune diabetes [44, 45]. However, we consider that, at the
present stage, our findings on the association of BPA and type
1 diabetes are inconclusive, because: [1] in our study setting
we could not control for the effect of sample storage on the
plasma BPA levels; and [2] the levels of BPAwere not quan-
tified. Clearly, further studies in clinical settings are merited in
order to establish the effect of exposure to BPA and other
environmental toxicants on the progression of type 1 diabetes
or other autoimmune diseases.
A potential limitation of our study is that we could not
profile microbiome or microbe-diet interactions that would
be likely to influence the circulatory metabolome of the new-
born infants. Future investigation of diet–microbe interactions
will be needed to clarify the impact of the microbial metabo-
lism that may potentially lower the microbial catabolites in
relation to the progression of type 1 diabetes. The statistical
limitations of the present study are connected with the rela-
tively low number of identified metabolites, a relatively small
sample size, which did not allow us to use a very strict FDR
(<0.05) cut-off, as well as random sampling because collec-
tion of fasting samples is not feasible in infants. Nevertheless,
this study generates novel hypotheses, which need further
validation in larger studies within heterogeneous populations.
Taken together, while confirming several earlier findings,
the present study highlights the importance of core metabolic
pathways such as amino and fatty acid metabolism in the early
pathogenesis of type 1 diabetes. We also observed that the
appearance of islet autoantibodies does have an effect on the
amino acid levels, specifically on glutamic and aspartic acids.
However, these changes do not seem to be specifically asso-
ciated with type 1 diabetes but are instead a general feature of
islet autoimmunity, suggesting that amino acid imbalance may
be a contributory factor in the initiation of autoimmunity [13].
Our study also indicates that the largest metabolic changes
associated with type 1 diabetes progression have already oc-
curred by early infancy, with these early metabolic signatures
becoming less pronounced or even disappearing with age.
This can be ascribed to the fact that dietary patterns could,
over time, mask some of the metabolic signatures associated
with type 1 diabetes or it might be related to the lack of insulin
in overt type 1 diabetes. Overall, these metabolic changes are
particularly apparent before the initiation of islet autoimmuni-
ty; this may have important implications for the search for
early metabolic markers of type 1 diabetes and for understand-
ing the disease pathogenesis.
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